Clinical Practice GuidelinesADA 2026 Pathway
Clinical Practice Guidelines • ADA 2026

ADA 2026 Standards of Care – Diagnostic Algorithm for Risk Stratification and Prevention of Cirrhosis in MASLD

American Diabetes Association 2026 (Section 4) screening pathway for adults with type 2 diabetes, prediabetes, or obesity with cardiovascular risk factors.

What This Means for Patients

Type 2 diabetes is one of the strongest accelerators of liver scarring, which is why the American Diabetes Association's 2026 Standards of Care builds liver fibrosis screening directly into routine diabetes visits. Even if your ALT and AST liver enzymes look completely normal, having type 2 diabetes, prediabetes, or obesity with a heart risk factor puts you in the group that benefits most from checking FIB-4 every 1 to 2 years — and moving to a FibroScan (8.0 kPa cutoff) or ELF test (9.8 cutoff) whenever FIB-4 is 1.3 or higher.

ADA 2026 Stepwise Screening & Referral Pathway (Section 4)

Step 1: Identify High-Risk Groups Screen even when ALT & AST are normal
Type 2 diabetes
Prediabetes
Obesity with ≥1 CV factor
↓ Before Staging
Rule out secondary causes of steatosis or ↑ALT

Evaluate alcohol intake (MetALD/PEth), steatogenic medications, viral hepatitis, iron, AAT, or autoimmune conditions.

Step 2: First- & Second-Line NITs Sequential blood calculation and liver stiffness testing
First-Line Check: Is FIB-4 ≥1.3?
No (FIB-4 <1.3) Lower risk of future cirrhosis
Yes — If FIB-4 >2.67 Direct Higher-Risk Referral
Yes — FIB-4 1.3–2.67 Proceed to LSM / ELF™ ↓
↓ Indeterminate FIB-4
Second-Line Check: Is LSM ≥8.0 kPa?a

(Or ELF™ ≥9.8 if elastography is unavailablea)

No (<8.0 kPa) Lower risk of future cirrhosis
Yes (≥8.0 kPa or ELF™ ≥9.8) Higher risk of future cirrhosis
Step 3: Care Team Management Matched to individualized cirrhosis & MASH risk
Lower Risk of Future Cirrhosis → Primary Care / Diabetes Team
  • Repeat FIB-4 every 1–2 years
  • Optimize lifestyle, ASCVD risk (statins safe!), and prioritize glucose/obesity therapies with MASH benefit (GLP-1 or dual GIP/GLP-1 RAs, pioglitazone)
Higher Risk of Future Cirrhosis → Liver Specialist + Interprofessional Team